JP2015509938A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509938A5
JP2015509938A5 JP2014557760A JP2014557760A JP2015509938A5 JP 2015509938 A5 JP2015509938 A5 JP 2015509938A5 JP 2014557760 A JP2014557760 A JP 2014557760A JP 2014557760 A JP2014557760 A JP 2014557760A JP 2015509938 A5 JP2015509938 A5 JP 2015509938A5
Authority
JP
Japan
Prior art keywords
seq
antibody
chain variable
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014557760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509938A (ja
JP6273214B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/026087 external-priority patent/WO2013123152A2/en
Publication of JP2015509938A publication Critical patent/JP2015509938A/ja
Publication of JP2015509938A5 publication Critical patent/JP2015509938A5/ja
Application granted granted Critical
Publication of JP6273214B2 publication Critical patent/JP6273214B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014557760A 2012-02-17 2013-02-14 がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用 Expired - Fee Related JP6273214B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600499P 2012-02-17 2012-02-17
US61/600,499 2012-02-17
US201261602511P 2012-02-23 2012-02-23
US61/602,511 2012-02-23
PCT/US2013/026087 WO2013123152A2 (en) 2012-02-17 2013-02-14 ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER

Publications (3)

Publication Number Publication Date
JP2015509938A JP2015509938A (ja) 2015-04-02
JP2015509938A5 true JP2015509938A5 (https=) 2016-01-28
JP6273214B2 JP6273214B2 (ja) 2018-01-31

Family

ID=48984888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557760A Expired - Fee Related JP6273214B2 (ja) 2012-02-17 2013-02-14 がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用

Country Status (13)

Country Link
US (5) US9493566B2 (https=)
EP (1) EP2814509B1 (https=)
JP (1) JP6273214B2 (https=)
KR (1) KR102084806B1 (https=)
CN (2) CN104220094A (https=)
AU (1) AU2013221585B2 (https=)
BR (1) BR112014019861A2 (https=)
CA (1) CA2862319C (https=)
EA (1) EA031069B1 (https=)
IL (1) IL233742B (https=)
MX (1) MX360141B (https=)
SG (1) SG11201404354UA (https=)
WO (1) WO2013123152A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012473A (es) 2008-05-23 2011-02-23 Siwa Corp Metodos, composiciones y aparato para facilitar la regeneracion.
AU2014331118B2 (en) * 2013-10-01 2019-07-25 Medimmune Limited Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer
ES2826398T3 (es) 2013-10-15 2021-05-18 Seagen Inc Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
SG10202001468UA (en) 2014-02-17 2020-04-29 Seattle Genetics Inc Hydrophilic antibody-drug conjugates
WO2015164627A1 (en) * 2014-04-23 2015-10-29 Discovery Genomics, Inc. Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
CN107001459B (zh) 2014-09-19 2021-11-23 Siwa有限公司 用于治疗炎症和自身免疫紊乱的抗age抗体
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
MX2019001302A (es) 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
TWI835714B (zh) 2016-10-18 2024-03-21 美商思進公司 菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
SI3535397T1 (sl) * 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
JP7445594B2 (ja) 2017-11-01 2024-03-07 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリンリガンドおよびその使用
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN111989339A (zh) 2018-02-20 2020-11-24 西雅图基因公司 疏水性奥瑞他汀f化合物及其缀合物
US20240199735A1 (en) * 2019-07-22 2024-06-20 The Methodist Hospital Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer
KR20220110231A (ko) * 2019-12-05 2022-08-05 씨젠 인크. 항-αvβ6 항체 및 항체-약물 접합체
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
WO2021207701A1 (en) 2020-04-10 2021-10-14 Seagen Inc. Charge variant linkers
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US12486502B2 (en) 2021-04-08 2025-12-02 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
AU2022262600A1 (en) 2021-04-20 2023-10-05 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
IL315508A (en) 2022-03-17 2024-11-01 Seagen Inc Camptothecin conjugates
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer
EP4731670A2 (en) 2023-06-23 2026-04-29 Mythic Therapeutics, Inc. Ph sensitive anti-itgb6 antibodies and uses thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
EE04752B1 (et) 1997-08-08 2006-12-15 The Regents Of The University Of California Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CN1646160A (zh) * 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US20040048312A1 (en) 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
US7241598B2 (en) * 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
EA200700751A1 (ru) * 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
PL1819359T3 (pl) * 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
KR20080039969A (ko) 2005-08-31 2008-05-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Ｇｌａ 도메인을 결합하는 인간 ｆｖｉｉ 단일클론의 항체및 이것의 사용
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
JP2010506944A (ja) 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
MX2010008025A (es) * 2008-01-22 2010-08-04 Biogen Idec Inc Anticuerpos ron y usos de los mismos.
WO2009119258A1 (ja) 2008-03-27 2009-10-01 テルモ株式会社 生体吸収性材料およびそれを用いた生体内留置物
CA2723842A1 (en) 2008-05-09 2009-11-12 Peter Vanlandschoot Amino acid sequences directed against integrins and uses thereof
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
KR101138460B1 (ko) 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
SG10201509499RA (en) 2010-11-19 2015-12-30 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
HK1208470A1 (en) 2012-03-29 2016-03-04 Biogen Ma Inc. Biomarkers for use in integrin therapy applications

Similar Documents

Publication Publication Date Title
JP2015509938A5 (https=)
JP2022093564A5 (https=)
JP2016536020A5 (https=)
CN115052893A (zh) 抗tigit抗体和使用方法
JP2014531201A5 (https=)
HRP20240924T1 (hr) Anti - sirpalpha antitijela
JP2017500028A5 (https=)
RU2016122041A (ru) Новые анти-клаудин антитела и способы их применения
JP2014511179A5 (https=)
JP2013529059A5 (https=)
JP2014509835A5 (https=)
JP2019513701A5 (https=)
JP2017519759A5 (https=)
JP2015504421A5 (https=)
JP2014522850A5 (https=)
HRP20221471T1 (hr) Protutijela anti-fgfr3 i postupci za njihovu uporabu
JP2017514461A5 (https=)
NZ714482A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
JP2014506120A5 (https=)
JP2013544492A5 (https=)
RU2016137110A (ru) Антитела к компоненту комплемента с5
HRP20240415T1 (hr) Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba
JP2018507188A5 (https=)
RU2016118573A (ru) Анти-ly6e антитела и способы применения
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas